摘要:

AbstractFrom February 1987 to January 1989, 60 patients with advanced breast cancer and no prior chemotherapy for advanced disease were randomized and studied, with 31 treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) and 29 patients with fluorouracil, mitoxantrone, and cyclophosphamide (FNC). Doses were 500 mg/m2fluorouracil, 500 mg/m2cyclophosphamide, and 50 mg/m2epirubicin2or 10 mg/m mitoxantrone, i.v. Day 1 every 3 weeks. There were no statistically significant differences in pretreatment patient characteristics between the groups. Fifty-six patients were evaluable for response (29 in the FEC arm and 27 in the FNC arm). The response rates were 48.2% for the FEC group (complete response (CR) 10.3% and partial response (PR) 37.9%) and 40.7% for the FNC group (CR 3.7% and PR 37%) (not significantly different, NS). The median response duration was 247 and 267 days, respectively (NS), the median time to progression and time to treatment failure was 244 and 155.5 days for the FEC group and 86 and 98 days for the FNC group, respectively (NS). The incidence of nausea/vomiting was 87.1% in the FEC group and 79.3% in the FNC group, with comparable severity. Alopecia occurred in 80.6% of FEC patients and 44.8% of FNC patients (p<0.05). The incidences and degrees of severity of leukopenia, anemia, and cardiotoxicity were comparable in the two treatment groups. Efficacy and toxicity of the two regimens were quite similar. FNC can improve the quality of life of patients by providing significantly less alopecia.

ISSN:0735-7907    

DOI:10.3109/07357909109021321

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractTreatment of gastric cancer still presents a challenge in cancer chemotherapy. In our Institute, from January 1981 to November 1984, 45 patients were given 5-fluorouracil (5FU) 600 mg/m2Days 1, 8, 29, and 36; doxorubicin (A) 30 mg/m2Days 1 and 29; mitomycin-C 10 mg/m2Day 1 (FAM regimen) every 8 weeks. From December 1984 to October 1986, 26 patients were treated with 5FU 300 mg/m2on Days 1–5, A 40 mg/m2on Day 1, cisplatin (P) 100 mg/m2on Day 1 (FAP regimen) every 3 weeks. In the FAM group, 42 patients are evaluable for response; 5 (12%) partial remission (PR), 9 stable disease (SD), and 28 progressions (PRO) were observed. Median duration of response (MDR) was 21 weeks (range 13–45) and the median survival (MS) in the whole group was 27 weeks. In the FAP group, 23 patients are evaluable: 2 CR (9%), 11 PR (47%), 2 SD (9%), and 8 PRO (34%) were observed; CR duration was 24 and 107+ weeks, respectively, MDR of PR was 22 weeks (5–35). The MS of all patients was 16 weeks. Toxicity (WHO criteria) was mild in the FAM group and severe in the FAP group. In spite of a higher objective response rate, the short MS and the severe toxicity observed in the FAP group do not merit recommendation of this regimen in patients with gastric cancer; therefore neither FAM nor FAP appear to be an ideal standard therapy.

ISSN:0735-7907    

DOI:10.3109/07357909109021322

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractA patient with fatal severe thrombocytopenia and acute hepatic necrosis complicating carboplatin (JM8, CBDCA, NSC 241240) therapy is described. The patient, an 18-year-old man with acute lymphocytic leukemia, was given high-dose carboplatin as a part of a phase I trial of this agent for the treatment of leukemia. Carboplatin (270 mg/m2/day) was administered as an intravenous infusion on five consecutive days, and the patient died 10 days after his last dose of carboplatin from complications of thrombocytopenia and acute liver necrosis. Autopsy revealed hemorrhage into the substance of the myocardium and hemorrhagic centrilobular liver necrosis. The temporal relationship between the initial rise in this patient's liver Junction tests and treatment with carboplatin suggests that this patient's liver failure was in part due to carboplatin. The autopsy findings of hemorrhage into the substance of the myocardium and centrolobular liver necrosis suggest that, in addition to its direct effects, carboplatin may have also contributed indirectly to this patient's liver failure through the complications of thrombocytopenia.

ISSN:0735-7907    

DOI:10.3109/07357909109021323

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractSeveral recent studies have indicated that alterations in expression of major histocompatibility complex (MHC) antigens by tumor cells affects the ability of the host to mount an effective antitumor immune response. To investigate whether newly induced tumors frequently exhibit altered MHC antigen expression, we used methylcholanthrene to induce a series of tumors and elevated MHC antigen expres- sion by these cells. The tumors exhibited a variety of MHC phenotypes in vitro. The nature of their phenotypes suggested that these cells were, in fact, capable of independent and abnormal regulation of MHC class 1 genes. However, when maintained in vivo, these same tumor cells expressed measurable levels of all of the appropriate MHC class I antigens. Thus, newly induced tumor cells are capable of abnormal MHC class I antigen expression. However, there was no obvious correlation between the phenotypes exhibited by these tumor cells in vitro and either their phenotype or their tumorigenic potential in vivo.

ISSN:0735-7907    

DOI:10.3109/07357909109021324

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109021325

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109021326

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109021327

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractThe purpose of this review is to describe and evaluate the antineoplastic properties of phenothiazines. The present research studies suggest that many phenothiazines do not show significant antitumor and antineoplastic activity and so they cannot be used as potential drugs to treat cancer. However some of their derivatives help indirectly in decreasing cytotoxic effects caused by radiation and other chemical carcinogens. Additionally, some phenothiazine derivatives provide protection against cancers caused by metabolic activation of carcinogens such as dimethylbenzanthracene. The selective accumulation of phenothiazine derivatives in certain tissues such as brain and melanoma tumors may provide an effective treatment of such tumors. Current studies suggest that highly potent phenothiazine derivatives can be made by nitro substitution on the aromatic ring of phenothiazines.

ISSN:0735-7907    

DOI:10.3109/07357909109021328

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109021329

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109021330

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor